Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein, which is lowly expressed in normal or hyperplastic prostate tissues, but highly expressed in prostate cancer.11 The expression of PSMA was reported to be positively correlated with the degree of malignancy, the tendency of metastasis, and the risk of early recurrence.12,13 In recent years, PSMA PET/CT imaging technology with PSMA as the molecular target has developed rapidly. Here, FOLH1 is linked to prostate carcinoma.